Milestone Pharmaceuticals is trading at $1.29 (6.2%) up today, rebounding after recent selling pressure tied to its Q1 earnings miss and CARDAMYST revenue disappointment.
- The move appears driven by improving broader market sentiment as major U.S. indices trade higher.
- With no new company-specific news or filings today, investors may be selectively bargain-hunting in beaten-down biotech names.
- The stock is recovering ground after prior weakness following the company's recent financial results.